Molecular Basis of Angiogenesis and its Application
Keio J Med. 2024;73(1):12. doi: 10.2302/kjm.ABSTRACT_73_1-1.ABSTRACTAngiogenesis, the development of new blood vessels, is a fundamental physiological process. In addition, angiogenesis plays a key role in the pathogenesis of several disorders, including cancer and eye disorders such as diabetic retinopathy and age-related macular degeneration (AMD). However, identifying the regulators of angiogenesis proved challenging. Numerous factors that stimulated angiogenesis in various bioassays were identified, but their pathophysiological role remained unclear. In 1989, we reported the isolation and cloning of vascular endothelia...
Source: The Keio Journal of Medicine - March 24, 2024 Category: Universities & Medical Training Authors: Napoleone Ferrara Source Type: research
Molecular Basis of Angiogenesis and its Application
Keio J Med. 2024;73(1):12. doi: 10.2302/kjm.ABSTRACT_73_1-1.ABSTRACTAngiogenesis, the development of new blood vessels, is a fundamental physiological process. In addition, angiogenesis plays a key role in the pathogenesis of several disorders, including cancer and eye disorders such as diabetic retinopathy and age-related macular degeneration (AMD). However, identifying the regulators of angiogenesis proved challenging. Numerous factors that stimulated angiogenesis in various bioassays were identified, but their pathophysiological role remained unclear. In 1989, we reported the isolation and cloning of vascular endothelia...
Source: The Keio Journal of Medicine - March 24, 2024 Category: Universities & Medical Training Authors: Napoleone Ferrara Source Type: research
Molecular Basis of Angiogenesis and its Application
Keio J Med. 2024;73(1):12. doi: 10.2302/kjm.ABSTRACT_73_1-1.ABSTRACTAngiogenesis, the development of new blood vessels, is a fundamental physiological process. In addition, angiogenesis plays a key role in the pathogenesis of several disorders, including cancer and eye disorders such as diabetic retinopathy and age-related macular degeneration (AMD). However, identifying the regulators of angiogenesis proved challenging. Numerous factors that stimulated angiogenesis in various bioassays were identified, but their pathophysiological role remained unclear. In 1989, we reported the isolation and cloning of vascular endothelia...
Source: The Keio Journal of Medicine - March 24, 2024 Category: Universities & Medical Training Authors: Napoleone Ferrara Source Type: research
Molecular Basis of Angiogenesis and its Application
Keio J Med. 2024;73(1):12. doi: 10.2302/kjm.ABSTRACT_73_1-1.ABSTRACTAngiogenesis, the development of new blood vessels, is a fundamental physiological process. In addition, angiogenesis plays a key role in the pathogenesis of several disorders, including cancer and eye disorders such as diabetic retinopathy and age-related macular degeneration (AMD). However, identifying the regulators of angiogenesis proved challenging. Numerous factors that stimulated angiogenesis in various bioassays were identified, but their pathophysiological role remained unclear. In 1989, we reported the isolation and cloning of vascular endothelia...
Source: The Keio Journal of Medicine - March 24, 2024 Category: Universities & Medical Training Authors: Napoleone Ferrara Source Type: research
Molecular Basis of Angiogenesis and its Application
Keio J Med. 2024;73(1):12. doi: 10.2302/kjm.ABSTRACT_73_1-1.ABSTRACTAngiogenesis, the development of new blood vessels, is a fundamental physiological process. In addition, angiogenesis plays a key role in the pathogenesis of several disorders, including cancer and eye disorders such as diabetic retinopathy and age-related macular degeneration (AMD). However, identifying the regulators of angiogenesis proved challenging. Numerous factors that stimulated angiogenesis in various bioassays were identified, but their pathophysiological role remained unclear. In 1989, we reported the isolation and cloning of vascular endothelia...
Source: The Keio Journal of Medicine - March 24, 2024 Category: Universities & Medical Training Authors: Napoleone Ferrara Source Type: research
Visual Outcome and Fluid Changes Between Eyes With Polypoidal Choroidal Vasculopathy Receiving Biosimilar CKD-701 or Reference Ranibizumab Therapy: A Post Hoc Analysis of a Phase 3 Randomized Clinical Trial
CONCLUSION: Biosimilar CKD-701 monotherapy resulted in comparable visual and anatomical changes to those achieved with reference ranibizumab in PCV eyes.PMID:38450631 | DOI:10.1080/02713683.2024.2323506 (Source: Current Eye Research)
Source: Current Eye Research - March 7, 2024 Category: Opthalmology Authors: Ki Tae Nam Cheolmin Yun Young Joo Lee Mihyun Choi Dongwan Kang Jaeryung Oh Source Type: research
Visual Outcome and Fluid Changes Between Eyes With Polypoidal Choroidal Vasculopathy Receiving Biosimilar CKD-701 or Reference Ranibizumab Therapy: A Post Hoc Analysis of a Phase 3 Randomized Clinical Trial
CONCLUSION: Biosimilar CKD-701 monotherapy resulted in comparable visual and anatomical changes to those achieved with reference ranibizumab in PCV eyes.PMID:38450631 | DOI:10.1080/02713683.2024.2323506 (Source: Current Eye Research)
Source: Current Eye Research - March 7, 2024 Category: Opthalmology Authors: Ki Tae Nam Cheolmin Yun Young Joo Lee Mihyun Choi Dongwan Kang Jaeryung Oh Source Type: research
Clinical evaluation of ranibizumab and conbercept for the treatment of macular oedema secondary to central retinal vein occlusion
Asian J Surg. 2024 Mar 5:S1015-9584(24)00383-X. doi: 10.1016/j.asjsur.2024.02.121. Online ahead of print.NO ABSTRACTPMID:38448288 | DOI:10.1016/j.asjsur.2024.02.121 (Source: Asian Journal of Surgery)
Source: Asian Journal of Surgery - March 6, 2024 Category: Surgery Authors: Ya Ye Zhen Huang Ming Yan Juan Yu Source Type: research
Comparative efficacy and safety of different anti-VEGF agents combined with different delivery methods for neovascular glaucoma: a systematic review and Bayesian network meta-analysis
Conclusion
ICCIVC was more effective and safer than other anti-VEGF regimens for NVG. Simultaneous intravitreal and intracameral injection was found to be the best route of administration, and conbercept was found to be the superior drug selection when compared with ranibizumab and bevacizumab.
PROSPERO registration number
CRD42022309676. (Source: BMJ Open)
Source: BMJ Open - March 4, 2024 Category: General Medicine Authors: Wang, J., Guo, Y.-M., Wei, J., Min, J., Ye, L. Tags: Open access, Ophthalmology Source Type: research
Biosimilar ranibizumab in India- overview of phase 3 clinical trial designs
Eye, Published online: 04 March 2024; doi:10.1038/s41433-024-03001-8Biosimilar ranibizumab in India- overview of phase 3 clinical trial designs (Source: Eye)
Source: Eye - March 4, 2024 Category: Opthalmology Authors: Ashish Sharma Nilesh Kumar Nikulaa Parachuri Francesco Bandello Anat Loewenstein Baruch D. Kuppermann Source Type: research
Comparison of different agents and doses of anti-vascular endothelial growth factors (aflibercept, bevacizumab, conbercept, ranibizumab) versus laser for retinopathy of prematurity: A network meta-analysis
Laser photocoagulation (LPC) and/or intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections constitute the current standard treatment for retinopathy of prematurity (ROP). This network meta-analysis focus on whether a ranking of interventions may be established for different dose levels of intravitreal injection of anti-VEGF agents (aflibercept, bevacizumab, conbercept, ranibizumab) as primary treatments for ROP versus laser in terms of retreatment rate as primary outcome, and time to retreatment and refractive error as secondary endpoints, since best anti-VEGF dosage remains under debate. (Source: Survey of Ophthalmology)
Source: Survey of Ophthalmology - March 1, 2024 Category: Opthalmology Authors: Amparo Ortiz-Seller, Pablo Martorell, Honorio Barranco, Isabel Pascual-Camps, Esteban Morcillo, Jos é L. Ortiz Tags: Review article Source Type: research
Branch retinal vein occlusion treated with anti VEGF, to switch or not to switch? Long term follow-up
CONCLUSIONS: Worse baseline BCVA is a significant predictor for anti-VEGF switch execution, though the switch has no significant impact on the change in BCVA over time. Multiple anti-VEGF switch is not recommended.PMID:38395414 | DOI:10.1016/j.jcjo.2024.01.016 (Source: Canadian Journal of Ophthalmology)
Source: Canadian Journal of Ophthalmology - February 23, 2024 Category: Opthalmology Authors: Reut Shor Ori Segal Dana Barequet Eran Greenbaum Omer Trivizki Anat Loewenstein Gilad Rabina Source Type: research
Infographic: Ranibizumab for macular edema following central retinal vein occlusion (CRUISE)
Eye, Published online: 23 February 2024; doi:10.1038/s41433-024-02990-wInfographic: Ranibizumab for macular edema following central retinal vein occlusion (CRUISE) (Source: Eye)
Source: Eye - February 23, 2024 Category: Opthalmology Authors: Robyn Gayle K. Dychiao Kei Gabrielle R. Crisostomo David Marco M. Magpantay Corrina P. Azarcon Jose Carlo M. Artiaga Source Type: research
The effect of leizumab on serum vascular endothelial growth factor, IL-6, MCP-1 inflammatory factors in neovascular glaucoma
This study aimed to assess Leizumab's effect on serum endothelial growth factor, interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1), and inflammatory factors in neovascular glaucoma patients. 80 eligible patients treated between January 2021 and April 2023 were enrolled, randomly divided into control and study groups. The control group underwent vitrectomy while the study group received preoperative intravitreal rituximab injection. Measurements included serum and aqueous humor VEGF/PEDF, IL-6/MCP-1 levels, postoperative rebleeding/retinal detachment, and visual acuity changes over 6 weeks. After surgery, patient...
Source: European Journal of Ophthalmology - February 12, 2024 Category: Opthalmology Authors: Junjie Bian Weijia Dai Dachuan Liu Source Type: research
The effect of leizumab on serum vascular endothelial growth factor, IL-6, MCP-1 inflammatory factors in neovascular glaucoma
This study aimed to assess Leizumab's effect on serum endothelial growth factor, interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1), and inflammatory factors in neovascular glaucoma patients. 80 eligible patients treated between January 2021 and April 2023 were enrolled, randomly divided into control and study groups. The control group underwent vitrectomy while the study group received preoperative intravitreal rituximab injection. Measurements included serum and aqueous humor VEGF/PEDF, IL-6/MCP-1 levels, postoperative rebleeding/retinal detachment, and visual acuity changes over 6 weeks. After surgery, patient...
Source: European Journal of Ophthalmology - February 12, 2024 Category: Opthalmology Authors: Junjie Bian Weijia Dai Dachuan Liu Source Type: research
